Archive

Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer

Dr. Eric Huang, Operating Partner at Delos, was awarded the 2022 Warren Alpert Foundation Prize

We would like to congratulate Dr. Eric Huang, Operating Partner at Delos Capital for being presented with the prestigious 2022 Warren Alpert Foundation Prize!   Each year the recipient(s) of the Warren Alpert Foundation Prize are recognized at a scientific symposium hosted by Harvard Medical School. 2022 WARREN ALPERT… Read More

Antios Therapeutics Appoints Gregory T. Mayes Chief Executive Officer

Former CEO and Antios co-founder, Abel De La Rosa, Ph.D., appointed Chairman of the Board of Directors Mayes to lead continued development of ATI-2173 as a potential backbone of a curative regimen for Hepatitis B (“HBV”) ATLANTA, Dec. 01, 2020 (GLOBE NEWSWIRE) — Antios Therapeutics, Inc. (“Antios”) today… Read More

OncoMyx Therapeutics Appoints Dr. Charles Baum Chairperson of Board of Directors

PHOENIX, November 6, 2020 – OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, today announced the appointment of Charles (Chuck) M. Baum, M.D., Ph.D., as chairperson of the company’s board of directors. Dr. Baum is currently president and chief executive officer of Mirati Therapeutics, which develops novel therapeutics that target the genetic… Read More